This study has simulated drug costs and healthcare costs for a 1 year course of adjuvant treatment with either IV biosimilar trastuzumab or SC reference trastuzumab in HER2-positive breast cancer patients in Belgium. The gene discussed is ERBB2; the disease is breast carcinoma.